On the contrary, lung carcinoma, while also subject to personalized approaches with drugs targeting EGFR mutations or ALK rearrangements and immunotherapy, generally shows lower overall response rates to chemotherapy compared to breast cancer. This evidence concerns the gene ALK and breast carcinoma.